Sonnet BioTherapeutics reports two out of three patients with platinum-resistant ovarian cancer (PROC) achieved a partial response (PR) in the E6 cohort of its Phase 1b/2a SB221 trial. This cohort evaluated SON-1010 (IL12-FHAB), the company’s lead immunotherapy candidate, in combination with atezolizumab at a 1200 ng/kg maintenance dose. Topline safety and cytokine data were also deemed acceptable.
The positive signal in a difficult-to-treat population like PROC—combined with acceptable safety at what was considered the maximum tolerated dose in the earlier monotherapy SB101 trial—prompted the addition of a new E7 cohort exploring a 25% higher dose (1500 ng/kg). This decision reflects an aggressive push by Sonnet to maximize efficacy before entering the randomized Phase 2a portion of the trial, which will compare the combination therapy (at either the E6 or E7 dose) against standard of care in PROC.
The underlying strategic tension here is the balance between maximizing the potential of the IL-12 payload while mitigating its well-known toxicity risks. SON-1010’s albumin-binding design aims to enhance tumor localization and reduce systemic exposure, but questions around optimal dosing persist, particularly in combination regimens. The expansion of both the SB221 (combination) and SB101 (monotherapy with trabectedin alternating in soft tissue sarcoma) studies suggests a bet on increased dose intensity to drive stronger responses, particularly in indications with limited treatment options.
The development impacts several stakeholder groups. For patients with PROC and STS, the data offer a glimmer of hope for new treatment modalities in cancers where immunotherapies have historically struggled to gain traction. For Sonnet, the results strengthen its position as it seeks partnership opportunities to fund later-stage development. This reliance on external funding underscores the resource constraints faced by smaller biotechs in advancing complex immunotherapies. The expansion also creates increased demands on trial sites to manage complex dosing regimens and monitor for cytokine-related adverse events.
Looking ahead, the E7 cohort will be crucial in defining the ultimate dose for the randomized Phase 2a study. Durability of responses and the full safety profile at higher doses remain critical open questions. While the preliminary efficacy signal is encouraging, demonstrating a statistically significant improvement over existing standards of care in a larger, randomized setting will be necessary for regulatory success. Sonnet’s success may also hinge on validating its FHAB platform’s ability to deliver potent immunomodulators with an acceptable safety profile, thereby opening doors for a new generation of targeted immunotherapies. The company’s pursuit of parallel development in multiple indications adds complexity but could also accelerate the platform’s overall validation if successful.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
